glp 1 drugs kidney disease GLP-1 receptor agonists in patients with chronic and either overweight or obesity TrimRX | Custom GLP-1 Dosing

For instance, in April 2026, according to data published by Lancet under the journal of public health in Germany, Germany's public health system faces challenges despite high spending, with rising rates of lifestyle-related diseases like obesity, smoking, and heart disease

Although there are drawbacks to taking GLP-1 drugs (such as muscle loss), they are viewed as a miracle drug by many who have struggled for years with obesity

Some researchers have highlighted post-treatment study findings that have shown that people tend to suffer from a high risk of weight regain after stopping these drugs

Understanding whether these effects are direct pharmacological actions or secondary to weight loss remains an important clinical question

JAMA 330 , 306 (2023)

Who Is a Candidate for GLP-1 Medications